<DOC>
	<DOCNO>NCT01741883</DOCNO>
	<brief_summary>The purpose study evaluate side effect prevention training ( SEPT ) optimize patient ' response expectation start adjuvant endocrine treatment ( AET ) prevent nocebo side effect enhance quality life long term drug intake .</brief_summary>
	<brief_title>Side Effect Prevention Training ( SEPT ) Nocebo Effects Breast Cancer Patients</brief_title>
	<detailed_description>The majority breast cancer patient discontinue today 's standard adjuvant treatment ( endocrine therapy ) due side effect reduce quality life . Thereby , side effect unspecific , thus , relate specific pharmacological action drug , individual treatment context patients´ expectation ( nocebo effect ) . The aim study evaluate side effect prevention training ( SEPT ) optimize patient ' response expectation start pharmacotherapy prevent nocebo side effect long term drug intake . Using randomized trial , study time course response expectation side effect breast cancer patient receive either SEPT , standard medical care attention-control intervention ( `` supportive therapy '' ) start adjuvant endocrine therapy . We analyze effect change pre-treatment expectation cancer-treatment related side effect , quality life adherence 3 6 month start endocrine therapy . Moderator analyse use determine predictor non-specific medication side effect patient high risk experience . Furthermore , explore mediate influence cop behaviour , thereby provide insight pathway clinical nocebo effect . The study finding promise significant advance clinical application nocebo research strong implication clinical research practice .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women estrogen receptor positive breast cancer schedule start firstline adjuvant endocrine therapy Tamoxifen ( +/ GnRH ) third generation Aromatase inhibitor Breast Cancer Centre Sufficient knowledge German language ability give inform consent Age 18 Presence serious comorbid psychiatric condition ( schizophrenia addiction , severe depression anxiety ) Presence life threaten comorbid medical condition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Patients´ Expectations</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Adjuvant Endocrine Treatment</keyword>
	<keyword>Nocebo</keyword>
</DOC>